• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

3v.org

Venture Capital Matters

  • Pitch a Startup
    • Make a Contribution
  • Startup Jobs
  • Market Reports
  • Technologies
    • Technology Events
  • Domain Names for Startups
  • About
    • How to raise venture capital
    • How to raise seed funding from angel investors
    • How private equity and venture capital firms operate
    • What is the difference between private equity and VC funding?
    • What technology trends are considered hot among VC firms?
    • What is elevator pitch?
    • What is startup burn rate?
    • Does failure to launch a startup spell the end of the entrepreneur’s ambitions?
    • How to avoid pitfalls in founding a startup
    • Why do startups fail?
    • What are the traits of successful startup founder?
    • What are startup vanity metrics?
    • Why investing in the next generation of women and diverse entrepreneurs is a crucial part to the success of the tech infrastructure
    • Where are VCs seeing opportunity
    • How do startup valuations work?
    • What is startup accelerator?
    • How to scale an early-stage startup team, how much to pay and how to distribute equity
    • Don’t mix business with friendship: when it comes to building a founding team for a startup, this adage may not always apply
    • What is a social unicorn?
    • Secure Your Startup’s Future: The Importance of Succession Planning
  • Contact

TISSIUM Closes €39M Series B Funding Round

November 19, 2019 By admin Leave a Comment

TISSIUM, a privately-owned life science company developing fully synthetic, biomorphic programmable polymers, announced today it has raised €38.75 million ($42.78 million) in a Series B round of funding. This funding round comprises new investors BNP Paribas Développement, the European Investment Fund (EIF), M&L Investments, ValQuest Partners in addition to TISSIUM’s returning investors Bpifrance, CM-CIC Innovation, CapDecisif Management, Omnes Capital and Sofinnova Partners.

The funding raised in this round will be used to support the Company’s global expansion of its platform of polymers across a variety of therapeutic fields, including nerve repair, cardiovascular and gastroenterology, among others.

The TISSIUM platform leverages proprietary technology, initially developed at the Massachusetts Institute of Technology (MIT) & Brigham and Women’s Hospital, Harvard Medical School, that serves as the foundation of a family of fully synthetic, biomorphic and programmable polymers. These polymers are designed to be used inside the body as sealants, adhesives, barriers, plugs or as a vehicle for drug delivery, as well as implantable devices created outside of the body using 3D printing technology.

In addition to supporting the growth of the platform, the funding is expected to support the broader strategy of creating a streamlined clinical development and regulatory process across multiple geographies. While the company remains headquartered in Paris, these efforts will also be focused towards the U.S. out of its newly opened Boston affiliate office.

Streamlined innovation and product development will also be simplified as a result of the completion of TISSIUM’s state-of-the-art manufacturing facility in Lille, France.

In addition, following the completion of the Series B, Jay Watkins, a serial Medtech entrepreneur and executive, is joining TISSIUM’s Board of Directors as Independent Chairman.

Christophe Bancel, CEO of TISSIUM, said: « This new round of funding is a testament to the support we continue to receive from investors for our strategy and vision for the broad TISSIUM ecosystem of products that we have in development. We look forward to moving swiftly towards multiple verticals and expanding into new clinical fields in the coming months.

We are thrilled to have Jay joining our board as Chairman. He brings tremendous experience and depth in building innovative Medtech companies into next generations leaders and will allow us to shape and expend our ecosystem into multiple verticals. I take the opportunity to thank our co-founder, Bernard Gilly, co-founder and Chairman of iBionext, who has led the company as its Chairman since our inception. »

Jay Watkins, Chairman of TISSIUM, added: « I am delighted to join TISSIUM as Chairman. I have been impressed with the breadth of applications for its biomorphic programmable polymers across a wide range of therapeutic fields. The organization has already demonstrated its ability to innovate and create novel product opportunities and I look forward to working with the team to extend our impact in the Medtech space. »

About TISSIUM:
TISSIUM is a privately-owned life sciences company based in Paris, France that is dedicated to the rapid development and commercialization of a unique biopolymer platform to address various unmet clinical needs.

The company’s platform is based on a proprietary polymer family with unique properties including the ability to conform to, and integrate with, surrounding tissue to enable natural healing. Furthermore, the modular design of the polymers enables customization to match tissue-specific requirements for different therapeutic areas. The company also develops delivery and activation devices for enhanced performance and usability of its family of polymers.

The Company’s technology is based on world-class research and intellectual property from the laboratories of Professor Robert Langer (MIT) and Professor Jeffrey M. Karp (Brigham and Women’s Hospital), who co-founded the company in 2013. For more information, please visit: www.TISSIUM.com

Filed Under: PR Tagged With: biomorphic programmable polymers, life science

Reader Interactions

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Primary Sidebar

Market Analysis

DevOps and Agile: Integrating Development and Operations
China’s Use of Golden Shares: From Reducing State Role to Quietly Controlling Tech Giants
Why Amazon Acquired One Medical: Disrupting the Healthcare Industry with Technology-Enabled Care
The End of an Era: Why China is No Longer Viable as the World’s Factory
Cloudflare’s FedRAMP authorization opens up a huge market opportunity in the US government sector
Datadog’s strong financial results for the fourth quarter and fiscal year 2022 provide a solid case for a Buy recommendation
Cisco: Struggling to find new avenues of growth

Market Research Media

Agile Leadership: Leading Agile Teams for Success
Chinese Brands Reach New Heights of Popularity in the West Amid Growing Political Tensions
Unrestricted Streaming: How VPNs Can Enhance Media Consumption Experience
How the world’s biggest companies have built and defended their moats
Virtual Learning Environments: A Game-Changer in Education?
Streaming video, training, and gaming coming together to form a cohesive and diverse media and entertainment ecosystem
Turn Your Story into a Game: The Art of Gamifying Your Plot

Secondary Sidebar

Technologies

Cloudflare Enters Fraud Detection Market with Cloudflare Fraud Detection
Devices utilizing Wi-Fi HaLow technology are gaining momentum
Agile Software Development Tools and Technologies
Continuous Integration and Continuous Delivery in Agile
NuScale Power places first long lead material production order for the manufacture of SMR

Tech Events

Splash User Conference and Partner Summit will take place from April 17 to 20, 2023 in Washington, D.C.
Fiber Connect 2023, August 20-23 2023, Orlando, Florida
International Battery Seminar & Exhibit (IBSE) on March 20-23, 2023 in Orlando, FL
MIT Technology Review’s Future Compute event, April 30 – May 1, 2023, MIT Campus, Cambridge, Massachusetts
13th Annual 2023 State IT Connect Summit in Baltimore, Maryland, from March 6-8, 2023

Footer

Recent Posts

  • African Venture Investment Soars to Record High, Fueled by Tech Startups
  • Pitchly Secures $7 Million Series A Funding for SaaS-Based Data Enablement Solution
  • Agile Project Management: Roles and Responsibilities
  • Candidly, a student debt and savings optimization platform, has raised $20.5 million in a Series B round of financing
  • GameTech Startups Attracting Venture Capital Funding: The Importance of VPN Security
  • Spreetail Secures $208M Funding to Enhance Ecommerce Acceleration Capabilities
  • Metomic secures $20 million in Series A funding to expand its SaaS data security solution in the US
  • The Texas A&M University System is set to create a boom in startups
  • Goose Insurance Services, a Vancouver-based insurance technology company, has recently closed a $4 million Series A funding round
  • Smile Identity, the leading identity verification platform in Africa, has raised $20 million in its Series B funding round

Dossier

Agile Coaching: The Key to Successful Agile Implementation
GameTech 2023, GameDev Conference, March 3, 2023
AI is Disrupting Software: Key Takeaways from Tech Summit 2023
indie Semiconductor has entered into a definitive agreement to purchase GEO Semiconductor
Why UK faces chronic labor shortages

Press Media Release

Webinar: Agile Software Development Metrics and Measurement
VPN Workshop Program Offers Comprehensive Training on VPN Technology
New Technology Job Board Launches to Connect Job Seekers with Top Employers
Media Release: Israelis Protest Proposed Judicial Reforms Amid Knesset Debate
S3H.com to Showcase Cutting-Edge Technology at MWC Barcelona 2023

App Coding

Common Pitfalls in Agile Development and How to Avoid Them
How Much Does It Cost to Build a FinTech App?
The annual GameTech Market 2023 is back and better than ever!
Appy Pie Introduces AI App Generator to Expedite App Development Process
Understanding Data Structures and Algorithms

API Coding

API governance is essential for ensuring the secure and reliable use of APIs
How to re-write a legacy API
How to Build API in Next.js
API Hub for Business Allowing Companies to Launch Custom Hubs in Minutes
How to built a gaming API

Copyright © 2022 3v.org

Technologies, Market Analysis & Market Research and Exclusive Domains

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
Cookie SettingsAccept
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT